Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma
C Bossley,Sejal Saglani,C. Kavanagh,Donald Payne,Nicola Wilson,Lemonia Tsartsali,M. Rosenthal,Ian M. Balfour-Lynn,Andrew G. Nicholson,Andrew Bush +9 more
TL;DR: Only 11% of DA children exhibited complete corticosteroid responsiveness, which suggests alternative therapies are needed for children with DA, according to a cross-sectional study on 102 patients.
Journal ArticleDOI
Anti-interleukin-5 therapy in severe asthma.
Gilles Garcia,Camille Taillé,Pierantonio Laveneziana,Arnaud Bourdin,Pascal Chanez,Marc Humbert +5 more
TL;DR: This review will consider new treatments options for severe asthma, particularly those targeting IL-5, that have already been evaluated in clinical trials in asthmatic patients.
Journal ArticleDOI
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation
Eli O. Meltzer,William W. Busse,Sally E. Wenzel,Vasily Belozeroff,Haoling H. Weng,JingYuan Feng,Yun Chon,Chiun-Fang Chiou,Shao-Lee Lin +8 more
TL;DR: The utility of the composite ACQ score measurement to predict risk of future exacerbation in clinical trials and clinical practice is found to be a better predictor of future risk than individual ACQ components.
Journal ArticleDOI
Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials.
TL;DR: Omalizumab is statistically significantly associated with symptom relief, decreased rescue medication use, and improvement of quality of life in patients with inadequately controlled allergic rhinosinusitis.
Journal ArticleDOI
Type 2 immunity in asthma.
TL;DR: This review will include an update on the relevance of dysregulation of innate and adaptive type 2-immunity in asthma pathogenesis, particularly severe asthma, and on the role of the allergens that are associated with severe asthma.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.